Search
HCW Biologics Inc
HCWBAdd to Watchlist
1.220USD
+0.883+261.99%
Market hours （ET）Quotes delayed by 15 min
3.20MMarket Cap
LossP/E TTM
More Details of HCW Biologics Inc Company
HCW Biologics Inc. is a clinical-stage biopharmaceutical company. It is focused on discovering and developing novel immunotherapies to lengthen the health span by disrupting the link between chronic, low-grade inflammation, and age-related diseases, such as cancer, cardiovascular diseases, diabetes, neurodegenerative diseases, autoimmune diseases, as well as other conditions. It has developed a Tissue factOr-Based fusion (TOBI) discovery platform to generate designer, novel multi-functional fusion molecules with immunotherapeutic properties. Its lead product candidates include HCW9218 and HCW9302. HCW9218 is a clinical-stage bifunctional molecule that is designed to impact senescence by reducing senescent cells. The Company is prepared to progress HCW9218 in Phase II clinical trials for non-oncology indications.HCW9302 is designed to activate and expand regulatory T cells, which deactivate inflammasomes. Its other product candidates include HCW9201, HCW9206, HCW11-006, and others.
HCW Biologics Inc Info
Ticker SymbolHCWB
Company nameHCW Biologics Inc
IPO dateJul 20, 2021
CEOWong (Hing C)
Number of employees36
Security typeOrdinary Share
Fiscal year-endJul 20
Address2929 N Commerce Pkwy
CityMIRAMAR
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code33025
Phone19548422024
Websitehttps://hcwbiologics.com/
Ticker SymbolHCWB
IPO dateJul 20, 2021
CEOWong (Hing C)
Company Executives of HCW Biologics Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Hing C. Wong, Ph.D.
Dr. Hing C. Wong, Ph.D.
Chief Executive Officer, Founder, Director
Chief Executive Officer, Founder, Director
501.91K
--
Ms. Rebecca Byam
Ms. Rebecca Byam
Chief Financial Officer
Chief Financial Officer
43.01K
--
Mr. Scott T. Garrett
Mr. Scott T. Garrett
Independent Chairman of the Board
Independent Chairman of the Board
25.50K
--
Mr. Lee Flowers
Mr. Lee Flowers
Senior Vice President - Business Development
Senior Vice President - Business Development
5.72K
+16.82%
Dr. Peter Rhode, Ph.D.
Dr. Peter Rhode, Ph.D.
Chief Scientific Officer, Vice President - Clinical Operations
Chief Scientific Officer, Vice President - Clinical Operations
1.94K
--
Ms. Lisa M. Giles
Ms. Lisa M. Giles
Independent Director
Independent Director
896.00
--
Mr. Rick S. Greene
Mr. Rick S. Greene
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Hing C. Wong, Ph.D.
Dr. Hing C. Wong, Ph.D.
Chief Executive Officer, Founder, Director
Chief Executive Officer, Founder, Director
501.91K
--
Ms. Rebecca Byam
Ms. Rebecca Byam
Chief Financial Officer
Chief Financial Officer
43.01K
--
Mr. Scott T. Garrett
Mr. Scott T. Garrett
Independent Chairman of the Board
Independent Chairman of the Board
25.50K
--
Mr. Lee Flowers
Mr. Lee Flowers
Senior Vice President - Business Development
Senior Vice President - Business Development
5.72K
+16.82%
Dr. Peter Rhode, Ph.D.
Dr. Peter Rhode, Ph.D.
Chief Scientific Officer, Vice President - Clinical Operations
Chief Scientific Officer, Vice President - Clinical Operations
1.94K
--
Ms. Lisa M. Giles
Ms. Lisa M. Giles
Independent Director
Independent Director
896.00
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Thu, May 14
Updated: Thu, May 14
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Wong (Hing C)
7.45%
Armistice Capital LLC
4.46%
Byam (Rebecca)
0.64%
DRW Securities, LLC
0.52%
Garrett (Scott T)
0.38%
Other
86.55%
Shareholders
Shareholders
Proportion
Wong (Hing C)
7.45%
Armistice Capital LLC
4.46%
Byam (Rebecca)
0.64%
DRW Securities, LLC
0.52%
Garrett (Scott T)
0.38%
Other
86.55%
Shareholder Types
Shareholders
Proportion
Individual Investor
8.69%
Hedge Fund
4.85%
Investment Advisor
1.61%
Investment Advisor/Hedge Fund
0.21%
Research Firm
0.01%
Other
84.63%
Institutional Shareholding
Updated: Wed, Apr 1
Updated: Wed, Apr 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2026Q1
39
465.64K
6.91%
+303.62K
2025Q4
36
125.21K
4.63%
+21.18K
2025Q3
35
36.93K
1.72%
-55.99K
2025Q2
40
613.16K
31.10%
+79.16K
2025Q1
40
480.61K
42.86%
-46.33K
2024Q4
37
23.10M
51.86%
+2.14M
2024Q3
33
21.13M
54.31%
+156.07K
2024Q2
33
21.19M
54.45%
+322.27K
2024Q1
34
20.93M
57.88%
+1.69M
2023Q4
33
19.30M
53.71%
+122.06K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Wong (Hing C)
501.91K
14.27%
--
--
Feb 17, 2026
Armistice Capital LLC
300.18K
8.54%
+300.18K
--
Dec 31, 2025
Byam (Rebecca)
43.01K
1.22%
--
--
Feb 17, 2026
DRW Securities, LLC
35.28K
1%
-48.16K
-57.71%
Dec 31, 2025
Garrett (Scott T)
25.50K
0.73%
--
--
Feb 17, 2026
Citadel Advisors LLC
22.16K
0.63%
+22.16K
--
Dec 31, 2025
Susquehanna International Group, LLP
20.07K
0.57%
+20.07K
--
Dec 31, 2025
Abante Asesores Gestión, S.G.I.I.C., S.A.
19.80K
0.56%
+19.80K
--
Dec 31, 2025
Geode Capital Management, L.L.C.
14.04K
0.4%
+3.04K
+27.60%
Dec 31, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
iShares Micro-Cap ETF
0%
iShares Micro-Cap ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Splits
Date
Ex-dividend Date
Type
Ratio
Apr 01, 2025
Merger
40→1
Date
Ex-dividend Date
Type
Ratio
Apr 01, 2025
Merger
40→1
